Status:
WITHDRAWN
GROW (Glioma Specialists Reaching Out With Support) Support
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Low-grade Glioma
Survivorship
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research study is being done to test a participant and caregiver-driven model of follow-up survivorship care,GROW Support (Glioma Specialists Reaching Out With Support), for post-treatment, low g...
Detailed Description
This research study is a Feasibility Study, which examines if a supportive intervention for people with low grade gliomas (LGGs) and their caregivers is acceptable and feasible to patients and their c...
Eligibility Criteria
Inclusion
- Patient inclusion criteria include:
- Must be at least 18 years of age;
- Diagnosed with low grade glioma (WHO grade 1 or 2)
- Completed active treatment within the last 2 years and are undergoing surveillance follow-up
- Must have at least one caregiver willing to participate as indicated below
- Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and are able to understand and willing to sign an electronic informed consent document.
- Confirms willingness to undergo initial and follow-up questionnaire battery.
- Caregiver inclusion criteria include:
- Must be at least 18 years of age
- Read and comprehend English such that they are able to complete required intervention sessions and psychosocial battery in English and able to understand and willing to sign an electronic informed consent document
- Consider themselves personally involved in the patient's care and decisions about the care they receive.
Exclusion
- Bipolar disorder,
- Psychotic disorders and
- Confusion or altered mental state that would prohibit understanding and giving of informed consent. However, if the patient's bipolar disorder or psychotic disorder is currently treated/managed, the patient will be eligible for the study.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 15 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05233215
Start Date
July 1 2022
End Date
June 15 2024
Last Update
January 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215